Going back on Mounjaro after a break: what to expect

What happens to weight when tirzepatide is paused?

The clearest evidence on this question comes from SURMOUNT-4, a withdrawal study designed specifically to test what happens when tirzepatide is stopped. Participants who had lost weight on tirzepatide and then switched to placebo regained, on average, around half the weight they had lost within a year. Those who continued on tirzepatide maintained their reduction. The NHS medicines page for tirzepatide is explicit that this is a long-term treatment, not a short course, and that stopping it is likely to be followed by weight regain.

That finding has a practical upside. If the drug worked for you, the biology has not changed. The GIP and GLP-1 receptors it activates are still there. Returning to treatment after a gap (whether the break was forced by a supply shortage, a surgical procedure, pregnancy planning, or simply life getting in the way) is not starting from scratch in the way that trying a new treatment would be, and our dedicated page on going back on Mounjaro walks through what that process looks like in practice. You have established tolerability data. Your prescriber can use that history.

What the evidence does not support is self-restarting at your previous dose without review. A prescriber needs to see where your weight, your health, and any relevant medications currently sit before writing a new prescription. That assessment is what makes restarting safe rather than just familiar. You can read more about the broader question of what happens during a Mounjaro break on a dedicated page.

What dose should you restart at after a gap?

This is the question our prescribers are asked most often in the context of returning patients. The short answer is that the length of the break determines the answer, and only a prescriber can confirm it for your specific situation.

As a general clinical principle drawn from the Mounjaro Summary of Product Characteristics on the eMC, if the gap between doses has been short (a week or two at most), most patients can resume without re-titrating. If the break has been longer (several weeks or months) the SmPC and standard clinical practice point toward re-titration from a lower dose, typically 2.5mg, to allow the gut to readjust. Jumping straight back to 10mg or 12.5mg after a three-month break is not supported by the prescribing guidance and is likely to produce significant nausea, vomiting, or worse.

There is also the matter of any medications started or changed during your break. Tirzepatide slows gastric emptying, which affects how oral medicines are absorbed. If you started a new oral contraceptive, a blood pressure tablet, or any other daily medicine while you were off tirzepatide, your prescriber needs to factor that in. The interaction between Mounjaro and progesterone-based medicines is one example worth raising at your review. The prescriber, not the patient, decides the restart dose. That is the rule, not a bureaucratic inconvenience.

Practical steps before your first pen back

Before you place a repeat order, check what you have at home. Mounjaro pens must be stored refrigerated between 2 and 8°C. If a pen has been sitting in a handbag or kitchen drawer since your break began, the storage window documented in the Patient Information Leaflet will determine whether it is still usable, always defer to that leaflet for the exact timeframe, because getting this wrong means injecting a degraded medicine. If there is any doubt, the pen should be disposed of safely and a fresh prescription ordered.

If your break was linked to a supply issue, it is worth reading about recent changes to Mounjaro pricing and availability in the UK before ordering, so that cost does not become a reason for another unplanned gap. Unplanned gaps are, according to the evidence, exactly what undermines long-term outcomes.

The practical process is straightforward. Book a clinical review, at nume, a GPhC-registered prescriber personally reads every consultation the same day. They will look at your history, your current health, and what dose makes sense. Once approved, treatment is dispatched the same day for free next-working-day delivery. No subscription. Every repeat is individually reviewed, which matters especially when a patient is returning after time away rather than continuing a steady routine. You can explore the specific eligibility considerations for returning patients in detail if you want more before booking.

Side effects on restart: what to anticipate

GI symptoms (nausea, loose stools, reflux, fatigue) are most common when tirzepatide is introduced or a dose is increased. Restarting after a significant break can behave similarly to a fresh introduction. Your system has partially lost its adaptation. This is not a sign that the medicine is no longer right for you; it is a sign that the dose ladder exists for good reason.

Going back through the lower doses, even briefly, is not a failure. It is how the medicine is designed to be used. Most people find that the GI discomfort settles within one to two weeks at each step, just as it did the first time. If it does not settle, or if you develop severe stomach pain that radiates to the back, seek medical attention promptly, the MHRA has highlighted acute pancreatitis as a known, infrequent but serious side effect of GLP-1 medicines, and a prescriber needs to know if this happens.

For a fuller picture of how tirzepatide works and what the restarting process involves clinically, the detailed guide to restarting Mounjaro covers the step-by-step process. And if you are weighing whether returning to Mounjaro is the right move at all, starting a free consultation with a prescriber is the clearest way to get an answer tailored to your situation.